2013
Cell Cycle Genes Coexpression in Multiple Myeloma and Plasma Cell Leukemia
KRYUKOV, Fedor; Elena Vladimirovna DEMENTYEVA; Lenka KUBICZKOVÁ; Sabina ŠEVČÍKOVÁ; Jiří JARKOVSKÝ et. al.Basic information
Original name
Cell Cycle Genes Coexpression in Multiple Myeloma and Plasma Cell Leukemia
Authors
KRYUKOV, Fedor; Elena Vladimirovna DEMENTYEVA; Lenka KUBICZKOVÁ; Sabina ŠEVČÍKOVÁ; Jiří JARKOVSKÝ; Lucie BROŽOVÁ; Pavel NĚMEC; Lenka ZAHRADOVÁ; Luděk POUR and Roman HÁJEK
Edition
14th International Myeloma Workshop, 2013
Other information
Language
English
Type of outcome
Conference abstract
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
Impact factor
Impact factor: 1.929
Organization unit
Faculty of Medicine
ISSN
Changed: 20/5/2013 12:32, Mgr. Anna Potáčová, Ph.D.
Abstract
In the original language
The regulation of cell cycle is dynamic and is determined not by the absolute level of any regulator, but by the aggregate balance between positive/negative cell-cycle regulators and the interplay among them. The objective of study was to describe coexpression correlations of cell cycle regulatory genes in MM and PCL. Chosen genes, responsible for G1-to-S cell-cycle progression, were divided into 2 groups based on their regulatory role: activators and blockers. Comparison of gene expression (qRT-PCR) in MM and PCL revealed up-regulation of CDKN2A (2.7-fold change, p=0.045) and CCND1 (7.9-fold change, p=0.005) in PCL samples. In PCL cohort, CCND1 and CDK6 expression lost correlation with blocker genes and CDKN1B expression lost correlation with activator genes. For CDKN2A and CDKN1A blocker genes loss of correlation with some activators were associated with significant increasing of correlation with other ones. Such reaction can be explained by compensation mechanisms. Univariate Cox proportional hazards survival model with one explanatory variable showed prognostic impact for CDKN2A (HR 1.022 [HR95%CI: 1.004; 1.040]; p=0.016) and CCND3 (HR 1.489 [HR95%CI: 1.112; 1.993]; p=0.008) in MM cohort. Thus, our data highlight changes in correlations between cell cycle blockers and activators during MM to PCL progression. Despite compensation mechanisms activation (CDKN2A, CDKN1A) whole regulatory complex seems to be imbalanced (CCND1, CDK6, CDKN1B), which can be explained by severe cell cycle dysregulation during progression to PCL.
Links
NT11154, research and development project |
| ||
NT13190, research and development project |
|